CA Stock MarketDetailed Quotes
NRX NurExone Biologic Inc
- 0.650
- +0.010+1.56%
15min DelayMarket Closed Jan 7 15:45 ET
46.08MMarket Cap-6.84P/E (TTM)
0.660High0.640Low29.31KVolume0.640Open0.640Pre Close18.99KTurnover1.19052wk High0.04%Turnover Ratio70.89MShares0.26052wk Low-0.095EPS TTM43.01MFloat Cap1.190Historical HighLossP/E (Static)66.17MShs Float0.100Historical Low-0.107EPS LYR3.13%Amplitude--Dividend TTM10.83P/B1Lot Size--Div YieldTTM
NurExone Biologic Inc Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -3.68%-818K | -25.00%-870K | -78.01%-1.47M | 23.57%-2.94M | 19.77%-633K | 5.05%-789K | 34.34%-696K | 29.54%-823K | -212.34%-3.85M | -44.24%-789K |
| Net income from continuing operations | -8.04%-1.25M | -27.40%-1.33M | -30.78%-922K | 55.45%-3.64M | 27.32%-737K | -11.14%-1.16M | 72.62%-1.04M | 69.55%-705K | -395.99%-8.17M | -12.04%-1.01M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 363.33%158K | -1,687.50%-127K |
| Depreciation and amortization | 0.00%18K | 116.67%13K | 150.00%15K | 450.00%33K | 200.00%3K | 800.00%18K | 100.00%6K | --6K | --6K | --1K |
| Remuneration paid in stock | 196.08%302K | -12.03%307K | 1,600.00%17K | 174.25%639K | 619.23%187K | 218.75%102K | 523.21%349K | -99.16%1K | 33.91%233K | -80.30%26K |
| Other non cashItems | --14K | --13K | 125.93%7K | -99.40%22K | -80.00%13K | ---- | ---- | -102.60%-27K | 30,625.00%3.69M | 400.00%65K |
| Change In working capital | -59.00%98K | 421.05%122K | -493.88%-582K | -98.31%4K | -138.08%-99K | 41.42%239K | 78.41%-38K | -512.50%-98K | -17.99%237K | 26.83%260K |
| -Change in receivables | 200.00%99K | -102.29%-3K | -92.71%-185K | -10.00%-11K | -164.23%-79K | -80.47%33K | 149.43%131K | -159.46%-96K | 81.82%-10K | 524.14%123K |
| -Change in payables and accrued expense | -115.81%-37K | 231.82%203K | -3,533.33%-309K | 262.07%47K | -40.00%-42K | 917.39%234K | -305.26%-154K | -43.75%9K | -111.28%-29K | -119.61%-30K |
| -Change in other current liabilities | ---- | ---- | ---19K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| -Change in other working capital | 228.57%36K | -546.67%-97K | -527.27%-69K | -111.59%-32K | -86.83%22K | -21.74%-28K | -111.81%-15K | -320.00%-11K | 217.24%276K | 106.17%167K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -3.68%-818K | -25.00%-870K | -78.01%-1.47M | 23.57%-2.94M | 19.77%-633K | 5.05%-789K | 34.34%-696K | 29.54%-823K | -212.34%-3.85M | -44.24%-789K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -30,200.00%-301K | -3,450.00%-71K | -363.46%-241K | -8.99%-97K | -833.33%-44K | 102.17%1K | 95.92%-2K | -52K | -368.42%-89K | 6K |
| Net PPE purchase and sale | -30,200.00%-301K | -2,950.00%-61K | -363.46%-241K | -130.77%-120K | -1,216.67%-67K | 111.11%1K | 95.92%-2K | ---52K | ---52K | --6K |
| Net other investing changes | --0 | ---- | ---- | 162.16%23K | ---- | ---- | ---- | ---- | -94.74%-37K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -30,200.00%-301K | -3,450.00%-71K | -363.46%-241K | -8.99%-97K | -833.33%-44K | 102.17%1K | 95.92%-2K | ---52K | -368.42%-89K | --6K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 19.79%1.26M | 4,500.00%44K | 55,075.00%4.4M | -73.64%1.13M | -8.16%90K | -36.57%1.05M | -100.05%-1K | -101.45%-8K | 24.03%4.3M | -96.27%98K |
| Net issuance payments of debt | 27.27%-8K | -600.00%-7K | 0.00%-8K | -129.17%-28K | ---8K | -266.67%-11K | -101.01%-1K | ---8K | -91.42%96K | --0 |
| Net common stock issuance | 3.66%764K | --0 | --566K | -68.25%740K | -98.59%3K | 4,435.29%737K | --0 | --0 | 4.72%2.33M | -84.82%213K |
| Proceeds from stock option exercised by employees | 50.46%489K | --15K | --3.84M | 119.59%325K | --0 | --325K | --0 | --0 | --148K | -1,216.67%-158K |
| Net other financing activities | --14K | ---- | ---- | -94.48%95K | ---- | ---- | ---- | ---- | 1,357.63%1.72M | --43K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 19.79%1.26M | 4,500.00%44K | 55,075.00%4.4M | -73.64%1.13M | -8.16%90K | -36.57%1.05M | -100.05%-1K | -101.45%-8K | 24.03%4.3M | -96.27%98K |
| Net cash flow | ||||||||||
| Beginning cash position | 171.02%2.39M | 104.97%3.26M | -78.03%541K | 11.25%2.46M | -63.73%1.14M | -78.10%880K | 1.66%1.59M | 11.25%2.46M | 110,600.00%2.21M | 2,269.17%3.15M |
| Current changes in cash | -46.77%140K | -28.33%-897K | 404.87%2.69M | -632.40%-1.91M | 14.31%-587K | -66.28%263K | -179.43%-699K | -43.11%-883K | -83.82%358K | -132.92%-685K |
| Effect of exchange rate changes | ---2K | 400.00%27K | 175.00%22K | 85.32%-16K | -400.00%-15K | --0 | 62.50%-9K | 122.86%8K | ---109K | ---3K |
| End cash Position | 120.73%2.52M | 171.02%2.39M | 104.97%3.26M | -78.03%541K | -78.03%541K | -63.73%1.14M | -78.10%880K | 1.66%1.59M | 11.25%2.46M | 11.25%2.46M |
| Free cash from | -42.01%-1.12M | -33.38%-931K | -94.97%-1.71M | 21.51%-3.06M | 10.60%-700K | 6.19%-788K | 37.06%-698K | 25.09%-875K | -216.56%-3.9M | -43.14%-783K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Price
% Chg
No Data